Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 1

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 5Leukemia, Myeloid, Acute 3Leukemia 2Waldenstrom Macroglobulinemia 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Leukemia, B-Cell 1Dendritic Cell Sarcoma, Interdigitating 1

Interventions

Cytarabine 7Daunorubicin 5Azacitidine 5venetoclax 3Decitabine 3ivosidenib 2decitabine and cedazuridine drug combination 2cedazuridine 2Mitoxantrone 2Idarubicin 2Etoposide 2treosulfan 1tagraxofusp 1revumenib 1quizartinib 1olutasidenib 1glasdegib 1gilteritinib 1fludarabine 1etoposide phosphate 1enasidenib 1cc-486 1Midazolam 1Itraconazole 1Granulocyte Colony-Stimulating Factor 1Gemtuzumab 1Drug Therapy 1Cobicistat 1CPX-351 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has announcements × Leukemia, Myeloid, Acute × venetoclax × Clear all
NCT02993523 2026-05-15

Viale-a

AbbVie

Phase 3 Completed
443 enrolled 14 charts 1 FDA
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04657081 2025-12-08

Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)

Taiho Oncology, Inc.

Phase 1/2 Active not recruiting
101 enrolled 1 FDA
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03069352 2025-09-30

A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

AbbVie

Phase 3 Completed
211 enrolled 30 charts 1 FDA
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡